Back to Agenda
[V4-S5] Development of Disease-Modifying Drugs for Alzheimer’s Disease (AD); Utilizing the Use of Biomarkers
Session Chair(s)
Yoshiko Komuro, PHD
Director, Office of Research Administration, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Developing a treatment for Alzheimer’s disease (AD) is an extremely critical issue as the world continues to age. Development of a disease-modifying drug that differs from the existing symptomatic drugs, by slowing or stopping disease progression is highly desired. For more than ten years, such disease-modifying drugs have been actively developed, but none have been approved. Difficulties in selecting appropriate patients and evaluating efficacy are considered the major reasons for this lack of approval. Recent studies utilized biomarkers that reflect the pathophysiological changes of AD to overcome some of these issues. This session will discuss the issues surrounding the development of disease-modifying drugs for AD, and points to consider while utilizing these biomarkers.
Speaker(s)
Haruhiko Akiyama, MD, PHD
Director, Department of Clinical Research, Yokohama Brain and Spine Center, Japan
Treatments of Alzheimer’s Disease: Current Therapy and Future Direction
Yoichi Inoue, JD, MD
Medical Affair, Japan, GE Healthcare Japan, Japan
Biomarkers of Alzheimer's Disease - Based on Imaging Technology
Ichiro Arano, PHD
Director, Primary Care, Clinical Operation, MSD K.K., Japan
Opportunities and Challenges of Biomarker in Development of Disease-Modifying Drugs for AD
Takaaki Suzuki, PHD
Reviewer, Office of New Drug II, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Have an account?